a post hoc analysis of adjuvant radiation therapy in the keynote-522 study
Published 1 year ago • 366 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
4:17
keynote-522: efs sensitivity & subgroup analyses
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
2:53
neoadjuvant chemoimmunotherapy: keynote-522, i-spy & more
-
0:41
the importance of brca-1 testing in triple negative breast cancer
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
3:49
keynote-522: neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs place...
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
0:50
phase i study of tak-676 pembrolizumab following radiotherapy in late-line nsclc, tnbc and scchn
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
0:43
management of residual disease in triple negative breast cancer